On August 13, PHARMARON rose 3.59% in regular trading, trading at HK$30.0/share, with turnover of HK$35.25 million.

On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its interim results for the first half of the year. The company previously guided H1 revenue of RMB 7.47 billion to RMB 7.67 billion, representing year-over-year growth of 16% to 19%, with newly signed orders rising over 30% and small-molecule CDMO new orders surging more than 50%.

Meanwhile, the CXO sector continues to strengthen broadly. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit growth of 29.43%, reinforcing the sector's improving fundamentals and driving valuation recovery across peers. On the same day, WuXi AppTec gained 1.36%, WuXi Biologics rose 0.57%, and GenScript Biotech advanced 2.33%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)